MA52796A - Compositions et procédés de détection d'une lésion cérébrale traumatique - Google Patents

Compositions et procédés de détection d'une lésion cérébrale traumatique

Info

Publication number
MA52796A
MA52796A MA052796A MA52796A MA52796A MA 52796 A MA52796 A MA 52796A MA 052796 A MA052796 A MA 052796A MA 52796 A MA52796 A MA 52796A MA 52796 A MA52796 A MA 52796A
Authority
MA
Morocco
Prior art keywords
compositions
detection
methods
brain injury
traumatic brain
Prior art date
Application number
MA052796A
Other languages
English (en)
Inventor
Lyndsay M Randolph
Suhail Rasool
Stella Sarraf
Original Assignee
Amydis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amydis Inc filed Critical Amydis Inc
Publication of MA52796A publication Critical patent/MA52796A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A61B3/12—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4058—Detecting, measuring or recording for evaluating the nervous system for evaluating the central nervous system
    • A61B5/4064—Evaluating the brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Eye Examination Apparatus (AREA)
MA052796A 2018-05-31 2019-05-31 Compositions et procédés de détection d'une lésion cérébrale traumatique MA52796A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862678900P 2018-05-31 2018-05-31
US201862733025P 2018-09-18 2018-09-18

Publications (1)

Publication Number Publication Date
MA52796A true MA52796A (fr) 2021-04-14

Family

ID=68697319

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052796A MA52796A (fr) 2018-05-31 2019-05-31 Compositions et procédés de détection d'une lésion cérébrale traumatique

Country Status (8)

Country Link
US (1) US20210369873A1 (fr)
EP (1) EP3803416A4 (fr)
JP (2) JP7381500B2 (fr)
CN (1) CN112424606A (fr)
AU (1) AU2019279001A1 (fr)
CA (1) CA3100700A1 (fr)
MA (1) MA52796A (fr)
WO (1) WO2019232422A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020093008A1 (fr) * 2018-11-02 2020-05-07 Sarraf Stella Composés de phosphate pour détecter des troubles neurologiques
EP4031879A4 (fr) * 2019-09-18 2023-11-15 Amydis, Inc. Méthodes de détection de troubles neurologiques par liaison à une protéine tau phosphorylée
CN117916225A (zh) * 2021-07-15 2024-04-19 阿米达斯公司 N-杂环基取代的2-氰基-3-(萘-2-基)丙烯酰胺衍生物作为荧光团用于检测类淀粉蛋白和类淀粉样蛋白以诊断神经退行性病症
WO2024155678A1 (fr) * 2023-01-18 2024-07-25 Amydis, Inc. Agents de ciblage d'amyloïde

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10047237A1 (de) * 2000-09-23 2002-04-11 Physoptics Opto Electronic Gmb System zur Aufnahme des Netzhautreflexbildes
AU2005310979A1 (en) * 2004-11-16 2006-06-08 Bellus Health (International) Limited Compounds for the treatment of CNS and amyloid associated diseases
EP2323696B1 (fr) * 2008-09-18 2018-09-05 Cedars-Sinai Medical Center Procédé optique pour la détection de la maladie d'alzheimer
US20120282169A1 (en) * 2009-11-06 2012-11-08 Adlyfe, Inc. Detection and treatment of traumatic brain injury
CN103201258B (zh) * 2009-12-10 2016-01-27 加利福尼亚大学董事会 淀粉状蛋白结合剂
EP2420179B1 (fr) * 2010-08-16 2020-10-07 Cognoptix, Inc. Système et procédé de détection de protéines d'amyloïdes
WO2012061078A2 (fr) * 2010-10-25 2012-05-10 Steven Verdooner Appareil et procédé de détection d'amyloïde dans une rétine dans un diagnostic, un avancement et un pronostic de la maladie d'alzheimer, d'une lésion cérébrale traumatique, d'une dégénérescence maculaire et d'une pluralité de maladies neurodégénératives, et de maladies oculaires
US9588129B2 (en) * 2013-03-15 2017-03-07 Amira Medical Technologies Inc. Methods for analyzing blood to detect diseases associated with abnormal protein aggregation
EP3068388A4 (fr) * 2013-11-11 2017-04-12 Board of Regents of the University of Texas System Composés neuroprotecteurs et leur utilisation
AU2015231239B2 (en) * 2014-03-19 2018-11-29 Amydis, Inc. Amyloid targeting agents and methods of using the same
US9605315B2 (en) * 2014-03-26 2017-03-28 The University Of Montana Detection of traumatic brain injury
WO2015188142A1 (fr) * 2014-06-05 2015-12-10 Cedars-Sinai Medical Center Diagnostic et surveillance d'une lésion cérébrale traumatique par imagerie des anomalies rétiniennes
EP3702786A1 (fr) * 2014-10-06 2020-09-02 Université de Genève Marqueurs et leur utilisation en lien avec une lésion cérébrale
WO2017004560A1 (fr) * 2015-07-02 2017-01-05 The Regents Of The University Of California Procédés et compositions pour des agrégats amyloïdes
GB201603967D0 (en) * 2016-03-08 2016-04-20 Univ Birmingham Biomarkers of traumatic brain injury
WO2020093008A1 (fr) * 2018-11-02 2020-05-07 Sarraf Stella Composés de phosphate pour détecter des troubles neurologiques

Also Published As

Publication number Publication date
CA3100700A1 (fr) 2019-12-05
CN112424606A (zh) 2021-02-26
WO2019232422A1 (fr) 2019-12-05
EP3803416A1 (fr) 2021-04-14
US20210369873A1 (en) 2021-12-02
JP2021525875A (ja) 2021-09-27
JP7381500B2 (ja) 2023-11-15
EP3803416A4 (fr) 2022-05-18
JP2024028695A (ja) 2024-03-05
AU2019279001A1 (en) 2020-12-03

Similar Documents

Publication Publication Date Title
MA52796A (fr) Compositions et procédés de détection d'une lésion cérébrale traumatique
MA46905A (fr) Compositions et procédés de synthèse de phosphoramidites et d'oligonucléotides
MA43822A (fr) Compositions et procédés de synthèse de phosphoramidite et d'oligonucléotides
MA52494A (fr) Formes solides d'un inhibiteur de fgfr et leurs procédés de préparation
MA46427A (fr) Compositions d'oligonucléotides et procédés associés
MA44990A (fr) Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-l1
MA51103A (fr) Compositions et procédés de traitement de l'atrophie musculaire et de la dystrophie myotonique
MA50636A (fr) Compositions et procédés pour inhiber l'activité d'arginase
MA45688A (fr) Compositions et procédés de potentialisation d'agents antimicrobiens
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
MA49045A (fr) Compositions et procédés destinés à la distribution régulée d'acide
MA45270A (fr) Compositions d'oligonucléotides et procédés associés
MA42269A (fr) Compositions et procédés d'inhibition de l'activité de l'arginase
MA51796A (fr) Procédés et compositions pour l'administration de protéines thérapeutiques
MA45798A (fr) Compositions et procédés d'inhibition de masp-3 pour le traitement de maladies et troubles divers
MA48779A (fr) Formes cristallines d'inhibiteur de fgfr et leurs procédés de préparation
MA44991A (fr) Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-1
MA44740A (fr) Variantes de capsides de virus adéno-associé et leurs procédés d'utilisation
MA49069A (fr) Procédés et compositions pour le traitement d'apnée du sommeil
MA53239A (fr) Procédés d'administration de certains inhibiteurs de vmat2
MA50045A (fr) Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
MA46791A (fr) Composés et procédés pour réduire l'expression d'atxn3
MA53445A (fr) Procédés et compositions pour la modification de plantes
MA50849A (fr) Substances et procédés pour le traitement d'hémoglobinopathies
MA44234A (fr) Procédés de traitement ou de prévention de l'athérosclérose par administration d'un inhibiteur d'angptl3